Enumeral Biomedical Corp
Enumeral Biomedical Holdings, Inc. is a Biotechnology company located at 200 CambridgePark Drive, Cambridge, Massachusetts 02140 United States
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.
Mr Derek BrandVP Business Development
E Squared Capital is an accomplished fund targeting emerging growth companies with potentially disruptive technologies or services. Founded in 2009, our flexible approach and team of seasoned professionals has particular expertise in finding unique solutions for public and private companies to accelerate growth, and significantly enhance shareholder valuation in a wide array of industries.
Our strategy includes not only investing our partners' capital, but sourcing capital from third parties. We support out investments with capital market advice and we develop creative solutions for companies seeking financing and operational expertise. These alliances offer unique access for company executives to better build and grow their businesses in an effective, strategic and thoughtful manner.
Mr Les FuntleyderPortfolio Manager
Innovative non-viral non-integrative gene therapy and DNA vaccination for treatment of severe human diseases based on proprietary set of expression technologies
Philippe JAISCEO, CSO
Your innovative solution
iGlide and the Cornea range bring innovative lamellar conservation and transportation solutions that make the corneal graft easier, quicker and more flexible. The cornea is trephined and pre-cut in the eye bank. Lamellar membrane is placed in the iGlide, conserved in the medium and sent to the physician.
iGlide saves time during surgeries, and isn
1/ Eye banks 2/ Other tissue brokers 3/ Surgeons 4/ Hospitals - GPO
1/ non invasive 2/ inexpensive 3/ no learning curve for surgeon 4/ Best quality for the eye banks and physicians
Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.
» Innovative leading cancer treatment response predictors
» Demonstrated medical utility in blood cancers
» CLIA certified tests for Acute Myeloid Leukemia
» Validated tests for Chronic Lymphocytic Leukemia
Mr Michael CardoneCo-founder, President and CEO
Evercore (NYSE:EVR) is a leading independent investment banking advisory firm. Evercore’s Investment Banking business advises its clients on mergers, acquisitions, divestitures, restructurings, financings, public offerings, private placements and other strategic transactions and also provides institutional investors with high quality equity research, sales and trading execution that is free of the conflicts created by proprietary activities. Evercore’s Investment Management business comprises wealth management, institutional asset management and private equity investing. Evercore serves a diverse set of clients around the world from 28 offices in North America, Europe, South America and Asia. More information about Evercore can be found on the Company’s website at www.evercore.com.
- Corporate Advisory
- Restructuring Advisory
- Evercore ISI
- Private Funds Group
- Private Capital Advisory
- Institutional Asset Management
• Atalanta Sosnoff Capital
• Evercore Trust Company
• Evercore Casa de Bolsa
- Wealth Management
• Evercore Wealth Management
- Private Equity
• Evercore Mexico Capital Partners
• Trilantic Capital Partners
Mr Scott LevittAssociate
ExSight Capital Management
Exsight Capital is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions.